EMA announces update on nitrosamine impurities in medicines
The EMA has released an update on nitrosamines in drugs, saying that work is continuing to prevent and manage these impurities.
List view / Grid view
The EMA has released an update on nitrosamines in drugs, saying that work is continuing to prevent and manage these impurities.
The US FDA will fund a research project using Raman spectroscopy and mass spectrometry to study drug delivery via the skin.
Safer sterility testing workflow. Reduce the risks when piercing product small sample packaging.
A report has suggested that number of Orphan Drug Designations in both the US and Europe is declining, possibly due to prices and political changes.
The FDA has released a statement, announcing that the US is experiencing its first shortage as a result of the effects of COVID-19.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
The MHRA has issued two alerts, one for incorrect maximum daily dosage of Ibuprofen 400mg and a second for missing safety information about Oxylan Prolonged-release tablets.
Advil Dual Action is the first FDA-approved an over-the-counter ibuprofen and acetaminophen combination, backed up with data from several clinical trials proving its efficacy.
Ranitidine tablets have been recalled due to the possibility of the products containing unacceptable levels of NDMA.
A warning letter has been sent by the US FDA to KVK-Tech regarding cGMP violations at their drug manufacturing site, including for data integrity.
The new Milliflex Oasis® system for bioburden and pharmaceutical water testing enables pharma QC labs to raise their productivity.
A statement by the Takeda reveals the company has acquired PvP as part of a development and option agreement for the drug TAK-062.
NICE has formed a negative opinion for Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine to treat diffuse large B-cell lymphoma.
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
An external review of the medicine Beovu has been announced by Novartis, which produces the drug, according to a new report.